Anthracycline Cardiotoxicity in a Patient with Diffuse Large B-Cell Lymphoma: A Case Report

Silva, Francisco Teixeira da; Passos, Rita Morais; Esteves, Alexandra; Carvalho, José Luiz de; Ferreira, Manuel

doi:10.7759/cureus.11038

Cited by 2 publications

(2 citation statements)

References 11 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some common drugs used to manage symptoms include ACE inhibitors, beta-blockers and diuretics in patients who experienced heart failure. Inotropes and vasopressors are also used in patients with biventricular failure and cardiogenic shock, and atropine is used in patients who experienced bradycardia 12 14 17. However, according to a literature review, the discontinuation of anthracycline therapy after cardiotoxic symptoms is a primary and significant intervention in limiting the damage in acute management stages 7…”

Section: Discussionmentioning

confidence: 99%

Rare complication of doxorubicin-induced complete heart block in a patient with Hodgkin’s lymphoma: a case report

et al. 2022

View full text Add to dashboard Cite

Anthracyclines are associated with cardiotoxic manifestations that are mainly dose-dependent, with onset varying from a few days to many years after stopping treatment. Frequent monitoring for toxic manifestations, early detection, cessation of anthracycline use and appropriate treatment is the key to preventing morbidity and mortality. Complete heart block with doxorubicin use in Hodgkin’s lymphoma is rarely reported, and is a severe toxic manifestation necessitating withdrawal or changing of regimen to etoposide + bleomycin + vinblastine + dacarbazine (EBVD), as in this case.

show abstract

Section: Discussionmentioning

confidence: 99%

Rare complication of doxorubicin-induced complete heart block in a patient with Hodgkin’s lymphoma: a case report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This patient too achieved significant improvement upon echocardiography performed 12 months after diagnosis showing improved heart contractility as well as increased LVEF to 60%. 44 Candesartan has also been associated with the preservation of LVEF when included in the treatment of patients undergoing anthracycline-based therapy with or without trastuzumab and radiation. Metoprolol, on the other hand, did not improve LVEF in these patients.…”

Section: Managementmentioning

confidence: 99%

Approach to Lymphoma-Associated Cardiomyopathy

Abouzid

Hameed

Katta

et al. 2022

Cardiology in Review

View full text Add to dashboard Cite

Cardiomyopathy is a disease of the myocardium that affects the heart structure and function, eventually resulting in heart failure, valvular regurgitation, arrhythmia, or even sudden cardiac death. Occurring following treatment of lymphoma, both Hodgkin's and Non-Hodgkin's, cardiomyopathy is a feared complication in these cancer survivors due to its significant association with morbidity and mortality. A review of the literature was conducted using a combination of keywords including "Cardiomyopathy," "Anthracycline," "Radiation," "Pathogenesis," and "Management." Anthracyclines and radiation are prominent entities explored in the discussion of lymphomaassociated cardiomyopathy, whereby the formation of reactive oxygen species following treatment with both has been seen in the pathogenesis. The current standard of care thus far for anthracycline-induced cardiomyopathy includes heart failure medications such as beta-blockers, angiotensin-converting enzyme inhibitors, aldosterone receptor antagonists, and loop-diuretics. On the other hand, radiation-induced cardiomyopathy management has not been well-established yet in literature, with agents such as antioxidants and antiinflammatory drugs still being studied in rat models. The treatment approach to cardiotoxicity in a lymphoma patient should consist of a collaboration between the oncologist and cardiologist prior to lymphoma treatment initiation, to stratify the risk of development of cardiomyopathy in the patient, and decide the best chemotherapy or radiotherapy agent, dosing, and surveillance technique.

show abstract

Anthracycline Cardiotoxicity in a Patient with Diffuse Large B-Cell Lymphoma: A Case Report

Abstract: Teixeira da Silva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Cited by 2 publications

References 11 publications

Rare complication of doxorubicin-induced complete heart block in a patient with Hodgkin’s lymphoma: a case report

Rare complication of doxorubicin-induced complete heart block in a patient with Hodgkin’s lymphoma: a case report

Approach to Lymphoma-Associated Cardiomyopathy

Contact Info

Product

Resources

About